propan-2-yl (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: propan-2-yl (2S)-2-[[(2S)-2-[(2S,3S)-2-[[(2R)-2-amino-3-sulfanylpropyl]amino]-3-methylpentoxy]-3-phenylpropanoyl]amino]-4-methylsulfonylbutanoate
• 化学式: C₂₆H₄₅N₃O₆S₂
• 分子量: 559.8
• InChiKey: PGOKBMWPBDRDGN-IBXSQZDTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  37
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  146
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
  申请人：Exonhit Therapeutics SA

  公开号：EP1656931A1

  公开（公告）日：2006-05-17

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone or in combination with other active agents or treatments.

  本发明涉及化合物及其用途，尤其是在制药业中的用途。本发明更具体地涉及抑制蛋白质的前酰化，特别是抑制蛋白质的香叶基和/或法呢基修饰的化合物的新用途，用于治疗涉及氧化应激的神经变性，特别是帕金森病。本发明还涉及相应的治疗方法，可用于人体的预防或治疗，可单独使用，也可与其他活性剂或治疗方法联合使用。
• COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE
  申请人：Exonhit Therapeutics SA

  公开号：EP1811984A1

  公开（公告）日：2007-08-01
• Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
  申请人：Dent Paul

  公开号：US20080139457A1

  公开（公告）日：2008-06-12

  The invention provides improved methods and compositions for the treatment of cancer in a subject comprising administering to said subject a therapeutically effective amount of a composition comprising a chorionic gonadotropin or a therapeutically active fragment or analogue thereof in combination with an HMG CoA reductase inhibitor. The compositions and methods may also comprise geranylgeranyltransferase inhibitors (GGTI) and farnesyltransferase inhibitors (FTI) instead of or in addition to the HMG CoA reductase inhibitors of the invention.
• Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease
  申请人：Schweighoffer Fabien

  公开号：US20080153758A1

  公开（公告）日：2008-06-26

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone is or in combination with other active agents or treatments.
• Methods of Treating Seizure Disorders
  申请人：Massachusetts Institute of Technology

  公开号：US20130225671A1

  公开（公告）日：2013-08-29

  Seizure disorders are treated by Ras inhibitors. In an embodiment, the Ras inhibitor includes a farnesyl transferase inhibitor. In another embodiment, the farnesyl transferase inhibitor includes a 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor. In another embodiment, the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase inhibitor is not a Ras inhibitor. Subjects having fragile X syndrome, autism, Angelman syndrome, Costello syndrome, cardio facio cutaneous syndrome, neurofibromatosis type I, Noonan syndrome and Coffin-Lowry syndrome that have seizure disorders can be treated.